Buy Indoco Remedies; target of Rs 430: Prabhudas Lilladher

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Prabhudas Lilladher's research report on Indoco Remedies

Indoco Remedies’ (INDR) H1FY23 performance was muted with +12% YoY decline in EBITDA (adj for forex gain). We expect margins to recover, led by softening of input prices and scale up of revenues. Domestic market (ex COVID) continues to grow. We remain structurally positive on INDR’s growth prospects given 1) MR productivity enhancement and higher penetration in North & East markets 2) new launches in US and 3) higher tender business in EU market.

Outlook

At CMP, stock is trading at 15.5x FY24E EPS. We reiterate our ‘Buy’ rating with unchanged TP of Rs430.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Indoco Remedies - 14 -11-2022 - prabhu